Pacira BioSciencesPCRX
PCRX
About: Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
Employees: 790
0
Funds holding %
of 7,419 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
696% more call options, than puts
Call options by funds: $19.8M | Put options by funds: $2.49M
22% more capital invested
Capital invested by funds: $768M [Q3] → $941M (+$172M) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]
1% less repeat investments, than reductions
Existing positions increased: 77 | Existing positions reduced: 78
2.46% less ownership
Funds ownership: 110.57% [Q3] → 108.12% (-2.46%) [Q4]
3% less funds holding
Funds holding: 237 [Q3] → 230 (-7) [Q4]
10% less first-time investments, than exits
New positions opened: 36 | Existing positions closed: 40
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$24
7%
downside
Avg. target
$37
41%
upside
High target
$65
151%
upside
4 analyst ratings
3 positive
75%
1 neutral
25%
0 negative
0%
Needham Serge Belanger 37% 1-year accuracy 45 / 123 met price target | 24%upside $32 | Buy Reiterated | 8 Apr 2025 |
HC Wainwright & Co. Oren Livnat 50% 1-year accuracy 25 / 50 met price target | 151%upside $65 | Buy Maintained | 8 Apr 2025 |
Barclays Balaji Prasad 16% 1-year accuracy 7 / 44 met price target | 7%downside $24 | Overweight Maintained | 28 Feb 2025 |
Truist Securities Les Sulewski 14% 1-year accuracy 1 / 7 met price target | 3%downside $25 | Hold Upgraded | 30 Jan 2025 |
Financial journalist opinion
Based on 17 articles about PCRX published over the past 30 days
Positive
Zacks Investment Research
16 hours ago
Why Pacira (PCRX) is Poised to Beat Earnings Estimates Again
Pacira (PCRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Neutral
PRNewsWire
21 hours ago
DOMA Perpetual Supports Pacira's New $300 Million Share Repurchase Authorization as a Meaningful Step to Enhance Value for Shareholders
DOMA Perpetual Believes Pacira's Stock Is Undervalued, Presenting an Opportunity to Execute the Largest Buyback in the Company's History MIAMI , April 21, 2025 /PRNewswire/ -- DOMA Perpetual Capital Management LLC (collectively with its affiliates, "DOMA Perpetual" or "We") is a fundamentals-based, value-oriented asset management firm which beneficially owns approximately 4.2% of the outstanding shares of common stock of Pacira BioSciences, Inc. (NASDAQ: PCRX ) ("Pacira" or the "Company"). Following constructive engagement with Pacira, DOMA Perpetual believes the Company's new capital allocation announcementi represents the Board's firm commitment to enhancing shareholder value.
Neutral
Accesswire
1 day ago
Pacira BioSciences, Inc. (PCRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
NEW YORK CITY, NY / ACCESS Newswire / April 20, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Pacira BioSciences, Inc. ("Pacira" or "the Company") (NASDAQ:PCRA). Investors who purchased Pacira securities prior to August 2, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/PCRA.
Neutral
GlobeNewsWire
4 days ago
Pacira BioSciences Reaffirms Commitment to Enhancing Value for All Shareholders
-- $300 million aggregate share repurchase authorization-- -- Reinforces confidence in 5x30 plan –
Neutral
Accesswire
4 days ago
Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRA) Shareholders to Inquire about Securities Investigation
NEW YORK CITY, NY / ACCESS Newswire / April 17, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Pacira BioSciences, Inc. ("Pacira" or "the Company") (NASDAQ:PCRA). Investors who purchased Pacira securities prior to August 2, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/PCRA.
Neutral
GlobeNewsWire
1 week ago
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., April 11, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today announced the granting of inducement awards on April 2, 2025 to 18 new employees under Pacira's Amended and Restated 2014 Inducement Plan (the “Inducement Plan”) as a material inducement to each employee's entry into employment with the company. In accordance with Nasdaq Listing Rule 5635(c)(4), the awards were approved by the People & Compensation Committee of the Board of Directors (the “Committee”) without stockholder approval.
Neutral
Accesswire
1 week ago
Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRA) Stockholders to Inquire about Securities Investigation
NEW YORK CITY, NY / ACCESS Newswire / April 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Pacira BioSciences, Inc. ("Pacira" or "the Company") (NASDAQ:PCRA). Investors who purchased Pacira securities prior to August 2, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/PCRA.
Positive
Seeking Alpha
1 week ago
Pacira BioSciences Remains A 'Buy' For Pain Management With The NOPAIN Act
PCRX focuses on non-opioid pain management with Exparel, Zilretta, and iovera, delivering targeted pain relief with fewer side effects. A key secular tailwind for them comes from the NOPAIN Act, which creates separate reimbursement and grows access to non-opioid therapies. Also, PCRX's PCRX-201 is a promising new gene therapy for knee osteoarthritis, which so far has shown promising results and targets a sizeable TAM.
Neutral
Zacks Investment Research
1 week ago
Pacira (PCRX) Surges 14.7%: Is This an Indication of Further Gains?
Pacira (PCRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Positive
Zacks Investment Research
1 week ago
PCRX Stock Soars on Exparel Patent Settlement With Generic Players
Pacira BioSciences stock rises as it settles Exparel patent litigation with several generic players protecting the drug's exclusivity in the United States at least until 2030.
Charts implemented using Lightweight Charts™